{"ok":true,"trend":{"id":720347,"platform":"news","region":"global","key":"immmunotherapy startup adecto blames ‘risk-adverse funding environment’ for closing down","title":"Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down","url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPZmxLekZrQTBFZUNaamJqdzlMcEsyMHItSVlyWXk5azZRZXNKTXBaY0dsbzREREJqSWxfVkJhU05RR2xvNnVIb0o3RjZGZW45Q1g5clIxUUdTUHVBbjcxUUlPdEM0bnRWQUxfRTlZV3JCSGhQVHVSNGdzOHhmZW9hQWlCajIwYmJUcDVFbjkzOUhWNXlVUklBZ0xHR21yWFhSU1RrbmJzakxZS21WbXYyYnB0MHJsTjdQbXA4VA?oc=5","first_seen":"2026-10-02T10:01:13.596405Z","last_seen":"2026-10-02T14:27:32.169002Z","last_rank":9,"peak_rank":5,"last_volume":null,"peak_volume":0,"seen_count":8,"score":58.85,"category_hint":"environment","section":"business","category":"startups","summary":"Immunotherapy startup Adecto has closed down, with the company pointing to a 'risk-adverse funding environment' as the reason for its collapse. The closure underscores growing pressure on early-stage biotech firms as investors pull back from risky drug development bets, raising concerns about how many promising treatments may stall for lack of capital.","why":"Biotech funding has tightened, and the startup's public blame of investors highlights wider worries about the sector's ability to raise money.","tone":"negative","entities":["Adecto"],"summarized_at":"2026-10-02T10:01:32.643533Z","meta":{"via":"scan","lang":"en","term":"environment","source":"Fierce Biotech","published":"Fri, 02 Oct 2026 07:53:11 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Immunotherapy startup Adecto shuts down, blaming risk-averse funding","section_name":"Business","category_name":"Startups","timeline":[{"captured_at":"2026-10-02T10:01:13.596405Z","rank":5,"volume":null},{"captured_at":"2026-10-02T10:21:10.988714Z","rank":5,"volume":null},{"captured_at":"2026-10-02T11:23:12.986633Z","rank":7,"volume":null},{"captured_at":"2026-10-02T11:43:10.451139Z","rank":5,"volume":null},{"captured_at":"2026-10-02T12:45:14.069347Z","rank":9,"volume":null},{"captured_at":"2026-10-02T13:05:10.200932Z","rank":6,"volume":null},{"captured_at":"2026-10-02T14:07:12.602059Z","rank":15,"volume":null},{"captured_at":"2026-10-02T14:27:32.169002Z","rank":9,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPZmxLekZrQTBFZUNaamJqdzlMcEsyMHItSVlyWXk5azZRZXNKTXBaY0dsbzREREJqSWxfVkJhU05RR2xvNnVIb0o3RjZGZW45Q1g5clIxUUdTUHVBbjcxUUlPdEM0bnRWQUxfRTlZV3JCSGhQVHVSNGdzOHhmZW9hQWlCajIwYmJUcDVFbjkzOUhWNXlVUklBZ0xHR21yWFhSU1RrbmJzakxZS21WbXYyYnB0MHJsTjdQbXA4VA?oc=5","author":"Fierce Biotech","title":"Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down","snippet":null,"posted_at":"2026-10-02T07:53:11Z","likes":null}],"elsewhere":[],"window":"7d"}}